20 Community News
Ponte Vedra Recorder ·September 24, 2015
Mayo Clinic awarded
grant to test new
breast cancer vaccine
CALL AGENTS FRANCES KING, CLARK EDWARDS OR MIKE BELL
Clinical trials expected
to begin early in 2016
Carrie Resch
The Recorder
150 Professional Dr #200
Ponte Vedra Beach FL 32082
904-249-0004
Exciting developments in the war
on cancer are being cultivated right
here on the First Coast.
On the cusp of National Breast
Cancer Awareness Month in Octo-
ber, the Mayo Clinic Florida campus has announced they have been
awarded a $13.3 million, five-year
federal grant to test a vaccine designed to prevent the recurrence of
triple-negative breast cancer.
“Continued improvements in
therapies for patients with triplenegative breast cancer are one of
our most important research goals,”
breast cancer researcher at the Mayo
Clinic Cancer Cent in Florida, Edith
Perez, M.D., said in a news release.
“We owe it to our patients to develop studies such as the ones that
will now be possible because of
this grant.”
Dr. Perez is a partner and principal investigator on the grant with
Keith Knutson, Pd.D, who designed
the vaccine and found that it was
safe and that it did not induce
autoimmunity, or failure of the
body’s immune system to recognize
its own cells and tissues as “self”
as some vaccines can, according
to the news release. The vaccine
was initially tested by researches at
Mayo Clinic’s Rochester, Minnesota
campus for safety and its ability to
stimulate the immune system.
Triple-negative breast cancer, or
TNBC, is missing the three most
common types of receptors known
to fuel most breast cancer growth:
estrogen, progesterone and HER2.
According to the breast cancer
advocacy group, Susan G. Komen,
abut 15-20 percent of all breast cancers in the U.S. are TNBC. Anyone
can get this type of breast cancer,
but research shows that it occurs
more often in younger women, African American women and women
who have BRCA1 gene mutations,
the organization reports.
The clinical trial to test the vaccine is expected to begin early in
2016. The clinical trial will enroll
280 patients at multiple clinic sites.
Send us
your news!
Plus tax and tag. 2 or more available, 39 month lease, no sec deposit, 10K miles per year. Total due at delivery: a) model 94715 $7,961, b) 84115 $6,837, c) 91115 $4,963. ends Sept. 30th, 2015.
Email
[email protected].